著者
内山 真一郎
出版者
日本神経学会
雑誌
臨床神経学 (ISSN:0009918X)
巻号頁・発行日
vol.50, no.11, pp.832-834, 2010 (Released:2011-03-28)
参考文献数
10
被引用文献数
1 6

We compared the efficacy and safety of cilostazol and aspirin in 2,672 Japanese patients with non-cardioembolic ischemic stroke. The patients were randomized to be allocated either on cilostazol (200mg/day) group or aspirin (81mg/day) group, and were followed up for one to five years (average 29 months). The primary endpoint was any stroke, and safety endpoint was hemorrhagic stroke or hemorrhage requiring hospitalization. Annual incidence of stroke was significantly lower in the cilostazol group (2.76%) than in the aspirin group (3.71%) (relative risk reduction [RRR] 25.7%, p=0.0357) and annual incidence of hemorrhagic stroke or hemorrhage requiring hospitalization was 0.77% in the cilostazol group and 1.77% in the aspirin group (RRR 54.2%, p=0.0004). The sub-analyses between subtypes of ischemic stroke showed that annual incidence of hemorrhagic stroke was much lower in the cilostazol group (0.36%) than in the aspirin group (1.20%) among patients with lacunar stroke (p=0.003). The results suggest that cilostazol has a favorable risk-benefit profile alternative to aspirin for secondary stroke prevention in patients with non-cardioembolic ischemic stroke, particularly in patients with lacunar stroke, who are at high risk of hemorrhagic stroke.

言及状況

外部データベース (DOI)

Twitter (1 users, 1 posts, 0 favorites)

https://t.co/dgwsvYC6ZW ぶら下げておきます。CSPS2試験の概要です。

Wikipedia (1 pages, 1 posts, 1 contributors)

編集者: Takuma-sa
2018-08-02 17:51:23 の編集で削除されたか、リンク先が変更された可能性があります。

収集済み URL リスト